OmniSeq News

Cancer-testis antigen detection by targeted RNA sequencing

Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors.  This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as...

read more

Cancer testis antigen co-expression landscape in solid tumors

Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for...

read more

OmniSeq Names Dr. Shengle Zhang as New Lab Director

FOR IMMEDIATE RELEASE MEDIA CONTACT: Sawyer Lipari Lambert & Co. 313.309.9551 slipari@lambert.com OmniSeq Names Dr. Shengle Zhang as New Lab Director Fast-growing cancer diagnostic laboratory continues focus on development of innovative product breakthroughs...

read more

Follow Us on Twitter

Check out how @OmniSeq and @RoswellPark are leveraging comprehensive immune profiling to identify potentially actionable targets for #mmunotherapy in pancreatic cancer. Download it here: https://lnkd.in/gHUjint
#Pancreatic #oncology #PrecisionMedicine

.@OmniSeq is partnering with the University of Pittsburgh Medical Center to employ a gene expression assay investigating the potential for personalized immunotherapy combinations for patients with head and neck squamous cell carcinoma. | @UPMC
https://www.cancernetwork.com/view/omniseq-employing-rna-sequencing-assay-to-investigate-personalized-immunotherapy-combos

In case you missed it! OmniSeq's webinar," Comprehensive Genomic and Immune Profiling to Support Drug Development" is now available to view at you convenience.
Just click: https://www.illumina.com/events/webinar/2021/cgs-drug-development.html
@illumina @ClinicalOMICs @Labcorp
#precisionmedicine
#oncology

FEBRUARY 9, 2021. 8:00 am PT, 11:00 am ET, 17:00 CET. REGISTR NOW to learn how @OmniSeq utilizes Genomic and Immune Profiling to support drug discovery.
https://www.linkedin.com/posts/omniseq-precision-medicine-technology_comprehensive-genomic-and-immune-profiling-activity-6762481167682867202-nclF
@illumina @ClinicalOMICs @Labcorp

Learn about the impact of a scalable comprehensive assay and infrastructure from Jeffery Conroy, Chief Scientific Officer of @OmniSeq.

Register for this @ClinicalOmics webinar, today.

Load More...